Saturday 17 October 2026
Export APLM’s income statement to Excel — free account
Apollomics Inc.
APLM Healthcare Biotechnology
Apollomics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $8.5 million, up 470.9% from fiscal 2024. Insiders bought in the last twelve months.
21.10
0.10
+0.48%
Follow APLM
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 985.00 | 989.00 | 55.00 | 6.50 | 3.66 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 998.60 | 1,050.00 | 4,900.00 | 105.00 | 42.12 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | 45 | 23 | 45 | 13 | 14 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.02 | 0.06 | 0.03 | 0.11 | 0.61 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | 2 | 1 | 1 | 1 | 1 | 9 | ||||
| Gross margin, % | — | — | — | — | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | |||||
| EBT | — | — | — | — | (75) | (95) | (241) | (173) | (54) | (11) | |||||
| EBT margin, % | — | — | — | — | (3,636.17) | (8,993.93) | (16,642.02) | (14,181.68) | (3,599.66) | (128.66) | |||||
| Net income | — | 0 | — | — | (75) | (95) | (241) | (173) | (54) | (11) | |||||
| Depreciation | — | — | — | — | 1 | 1 | 1 | 1 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.57 | 0.26 | 5.07 | 1.64 | 1.46 | 5.88 | ||||
| Earnings | — | — | — | — | (20.70) | (23.45) | (844.12) | (232.00) | (52.80) | (7.57) | |||||
| Cash flow | — | — | — | — | (9.87) | (10.72) | (150.10) | (58.08) | (28.18) | (7.17) | |||||
| Capex | — | — | — | — | (2.81) | (1.87) | (1.29) | 0.07 | (0.02) | 0.03 | |||||
| Free cash flow | — | — | — | — | (12.68) | (12.58) | (151.39) | (58.01) | (28.20) | (7.14) | |||||
| Book value | — | — | — | — | (35.39) | (52.66) | (1,570.70) | 55.42 | 4.77 | (2.20) | |||||
| Shares, m | — | — | — | — | 4 | 4 | 0 | 1 | 1 | 1 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| P/B | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| EV/Sales | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| EV/FCF | — | — | — | — | 0.00 | 0.00 | 0.81 | 0.30 | 0.06 | 0.00 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | (36) | (43) | (43) | (43) | (29) | (10) | ||||
| Capex | — | — | — | — | (10) | (8) | 0 | 0 | 0 | 0 | |||||
| Free cash flow | — | — | — | — | (46) | (51) | (43) | (43) | (29) | (10) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 146 | 86 | 43 | 26 | 3 | 0 | ||||
| Total debt | — | — | — | — | — | — | — | 4 | — | — | |||||
| Net debt | — | — | — | — | (154) | (70) | (52) | (34) | (10) | (3) | |||||
| Shareholders’ equity | — | — | — | — | (128) | (213) | (448) | 41 | 5 | (3) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | (88.05) | (64.62) | (240.92) | (261.79) | (157.28) | (110.43) | ||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | (415.11) | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | 0.00 | 55.63 | 72.86 | 84.84 | (233.67) | (1,305.45) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · fundamentals updated 1 Oct 2026
Charts ten years each
Apollomics Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| VRCA Verrica Pharmaceuticals Inc. | $64.9M | — (loss-making) | — (loss-making) | −53.85% (below 0%: shrinking) | n/m | +7.63% (above 0%: growing) | 85.02% | (223.42%) | Compare |
| CING Cingulate Inc. | $63.8M | — (loss-making) | — | — | n/m | −24.28% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| FBIO Fortress Biotech, Inc. | $63.7M | 0.6× | 1.1× | +14.04% (above 0%: growing) | n/m | −115.37% (below 0%: shrinking) | 67.18% | (53.46%) | Compare |
| APLM Apollomics Inc. | $61.2M | — (loss-making) | — | — | 0.00% | +76.08% (above 0%: growing) | — | — | |
| BMEA Biomea Fusion, Inc. | $60.6M | — (loss-making) | — | — | n/m | +47.80% (above 0%: growing) | 0.00% | 0.00% | Compare |
| PLRX Pliant Therapeutics, Inc. | $60.2M | — (loss-making) | — (loss-making) | −95.03% (below 0%: shrinking) | n/m | +68.61% (above 0%: growing) | 0.00% | 0.00% | Compare |
| XLO Xilio Therapeutics, Inc. | $59.4M | — (loss-making) | — (loss-making) | +131.22% (above 0%: growing) | n/m | −26.23% (below 0%: shrinking) | 100.00% | (18.68%) | Compare |
| GANX Gain Therapeutics, Inc. | $58.1M | — (loss-making) | — (loss-making) | +27.78% (above 0%: growing) | n/m | +8.22% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CNTB Connect Biopharma Holdings Limited Sponsored ADR | $57.1M | — (loss-making) | — (loss-making) | +296.56% (above 0%: growing) | n/m | −23.48% (below 0%: shrinking) | 100.00% | (635.98%) | Compare |
| Median of peers | $60.4M | — | — | +20.91% | — | −7.92% | 33.59% | (9.34%) |
Apollomics Inc. (APLM) key facts
- Strength: Apollomics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $8.5 million, up 470.9% from fiscal 2024.
- Apollomics Inc. (APLM) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, APLM traded at $21.10, a market capitalization of $61.2 million.
- Return on equity was −1,305.5% and debt-to-equity 0.00.
- Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −150.05 (distress zone) for fiscal 2025.